Home GPCR & G Protein Vasopressin Receptor

Vasopressin Receptor

Isoform-selective Products

Signaling Pathway

Vasopressin Receptor Signaling Pathway

Vasopressin Receptor Products

  • All (6)
  • Vasopressin Receptor Antagonists (6)
  • New Vasopressin Receptor Products
Catalog No. Product Name Information Product Use Citations Product Validations
S2593 Tolvaptan Tolvaptan (OPC-41061) is an orally effective nonpeptide arginine vasopressin V2 receptor antagonist with IC50 of 3 nM, used to treat hyponatremia.
Acta Physiol (Oxf), 2021, 10.1111/apha.13661
J Mol Cell Biol, 2020, 12(8):644-653
Am J Physiol Renal Physiol, 2015, 309(5):F474-83
S2116 Conivaptan HCl Conivaptan HCl(YM 087) is an orally active, non-peptide, vasopressin V1A and V2 receptor antagonist, used in the treatment of euvolemic and hypervolemic hyponatremia.
Cell Res, 2022, 1-17
Antimicrob Agents Chemother, 2017, AAC.01674-17
Sci Rep, 2017, 7(1):12881
S2920 Mozavaptan Mozavaptan (OPC-31260) is a novel competitive vasopressin receptor antagonist for both V1 and V2 receptors with IC50 of 1.2 μM and 14 nM, respectively.
Life Sci, 2019, 10.1016/j.lfs.2019.05.049
Am J Med Sci, 2019, 357(3):247-254
S0007 RO 5028442 (RG7713) RO 5028442 (RG7713) is a highly potent and selective Brain-Penetrant Vasopressin 1a (V1a) receptor antagonist with Kis of 1 nM for hV1a and 39 nM for mV1a.
S2815 Lixivaptan (VPA-985) Lixivaptan (VPA-985, CRTX 080, WAY VPA 985) is an oral, non-peptide, selective V2 receptor vasopressin antagonist with IC50s of 1.2 nM and 2.3 nM for human V2 receptor and rat V2 receptor, respectively.
E4957New Mozavaptan (hydrochloride) Mozavaptan hydrochloride(OPC 31260 HCl), a benzazepine derivative is a potent, selective, competitive, and orally active antagonist of vasopressin V2 receptor with an IC50 value of 14 nM. Mozavaptan hydrochloride shows ~85-fold selectivity for V2 receptor over V1 receptor. Mozavaptan hydrochloride has the potential for hyponatremia, syndrome of inappropriate antidiuretic hormone (SIADH), and congestive heart failure treatment.
S2593 Tolvaptan Tolvaptan (OPC-41061) is an orally effective nonpeptide arginine vasopressin V2 receptor antagonist with IC50 of 3 nM, used to treat hyponatremia.
Acta Physiol (Oxf), 2021, 10.1111/apha.13661
J Mol Cell Biol, 2020, 12(8):644-653
Am J Physiol Renal Physiol, 2015, 309(5):F474-83
S2116 Conivaptan HCl Conivaptan HCl(YM 087) is an orally active, non-peptide, vasopressin V1A and V2 receptor antagonist, used in the treatment of euvolemic and hypervolemic hyponatremia.
Cell Res, 2022, 1-17
Antimicrob Agents Chemother, 2017, AAC.01674-17
Sci Rep, 2017, 7(1):12881
S2920 Mozavaptan Mozavaptan (OPC-31260) is a novel competitive vasopressin receptor antagonist for both V1 and V2 receptors with IC50 of 1.2 μM and 14 nM, respectively.
Life Sci, 2019, 10.1016/j.lfs.2019.05.049
Am J Med Sci, 2019, 357(3):247-254
S0007 RO 5028442 (RG7713) RO 5028442 (RG7713) is a highly potent and selective Brain-Penetrant Vasopressin 1a (V1a) receptor antagonist with Kis of 1 nM for hV1a and 39 nM for mV1a.
S2815 Lixivaptan (VPA-985) Lixivaptan (VPA-985, CRTX 080, WAY VPA 985) is an oral, non-peptide, selective V2 receptor vasopressin antagonist with IC50s of 1.2 nM and 2.3 nM for human V2 receptor and rat V2 receptor, respectively.
E4957New Mozavaptan (hydrochloride) Mozavaptan hydrochloride(OPC 31260 HCl), a benzazepine derivative is a potent, selective, competitive, and orally active antagonist of vasopressin V2 receptor with an IC50 value of 14 nM. Mozavaptan hydrochloride shows ~85-fold selectivity for V2 receptor over V1 receptor. Mozavaptan hydrochloride has the potential for hyponatremia, syndrome of inappropriate antidiuretic hormone (SIADH), and congestive heart failure treatment.
E4957New Mozavaptan (hydrochloride) Mozavaptan hydrochloride(OPC 31260 HCl), a benzazepine derivative is a potent, selective, competitive, and orally active antagonist of vasopressin V2 receptor with an IC50 value of 14 nM. Mozavaptan hydrochloride shows ~85-fold selectivity for V2 receptor over V1 receptor. Mozavaptan hydrochloride has the potential for hyponatremia, syndrome of inappropriate antidiuretic hormone (SIADH), and congestive heart failure treatment.

Choose Selective Vasopressin Receptor Inhibitors

Tags: Vasopressin Receptor inhibitor|Vasopressin Receptor agonist|Vasopressin Receptor activator|Vasopressin Receptor inducer|Vasopressin Receptor antagonist|Vasopressin Receptor signaling pathway|Vasopressin Receptor assay kit